June: CAR T cells are derived from our own immune system. T cells are a type of white blood cell that give our bodies lifelong memory to infections. CAR T takes those immune cells and makes them cancer killers. The cells divide when they find their targets; a single cell can turn into a billion cells, so you can make an entire army of cancer killers from one cell. All the cells—and all their descendants—are identical.
We found that the CAR T cells survived in some of the first patients treated—back in 2010—for more than a decade. So, we can really say CAR T cells are a living drug. CAR T cell therapy has exquisite selectivity for blood cancers—meaning it does a good job of only attacking cancer cells—and because it doesn’t affect healthy cells, it doesn't cause the same side effects chemotherapy does. That that's been a major paradigm shift.
June: CAR T cell therapy has been remarkably successful for blood cancers like leukemias and lymphomas. There’s a lot of work happening here at Penn and elsewhere to push it to other blood cancers and to earlier stage disease, so patients don’t have to go through chemo first. Another big priority is patients with solid tumors because they make up the vast majority of cancer patients.
Beyond cancer, we’re seeing early signs that CAR T cell therapy could work in autoimmune diseases, like lupus. In lupus, immune cells target the patient’s own DNA, creating antibodies against their DNA, which leads to tissue damage. CAR T cell therapy could be used to target the cells that make those autoimmune antibodies and kill them, which should resolve the tissue damage. And that's exactly what the early trials are showing.
Essentially it boils down to two questions: Can we identify a population of cells that are bad? And can we target them specifically? Whether that’s asthma or chronic diseases or lupus, if you can find a bad population of cells and get rid of them, then CAR T cells could be therapeutic in that context.
Baker: What’s exciting is it's not just theoretical at this point. There have been clinical reports in other autoimmune diseases, including myasthenia gravis and inflammatory myopathy. It's still early, and we're not going to know for a while whether these are curative, or what the long-term effects are going to be.
But we are seeing early evidence that CAR T cell therapy will be successful beyond cancer. And it's really opening the minds of people in the field to think about how else we could use CAR T. For example, there’s some pioneering work at Penn from the Epstein lab for heart failure. The idea is that you could use CAR T cells to get rid of fibrotic tissue after a cardiac injury, and potentially restore the damage following a heart attack.
June: I’d put the current limitations into two main baskets: One is scientific knowledge. And the other is really an engineering issue of scaling out manufacturing access so that it's accessible to more patients.
The science is rapidly being solved. Back when we started, there were less than a handful of groups working on CAR T in the entire world. Now, thousands of laboratories are working on this. While the science is most effectively addressed in academic settings, where innovation occurs more rapidly, the progress on manufacturing is happening primarily within the biopharma industry. CAR T cells are currently made using the process we developed in the 1990s. It was an academic process that was not designed to be brought to scale. It’s heavily dependent on highly trained scientists and technicians, so there's a workforce limitation to meet the demand for therapy. One obvious solution is automation. The biopharma industry is working to make “plug and play” instruments that would take blood from the patient and manufacture the CAR T cells in an automated fashion, without the need for human intervention.
Also, for any new paradigm-shifting therapy, you have to train the physicians and nurses on how to deliver it efficiently. It usually takes about a decade to transfer that level of knowledge from major cancer centers out to more rural areas. We’re in the midst of that right now with CAR T cell therapy. Clinicians also get better at treating side effects from new therapies over time. In the early days of our CAR T cell clinical trials, 20-30 percent of patients would have to go to the ICU to treat cytokine release syndrome (CRS), a side effect that happens when the immune system overreacts. Now, it’s much less because clinicians have learned how to treat it.
Finally, the workforce is now hiring many more people to work on cell therapy. I’ve had 55 grad students in my lab since coming to Penn. When we started in 1999, if people asked about coming to my lab to work on CAR T cells, others in the field would tell them not to because it was just an academic curiosity. There was no industry or pipeline of jobs, and now that’s completely changed. Now this field is attracting many young talented trainees such as Daniel, who are really increasing the pace of innovation this area.
Baker: I was in high school when the first patients were treated with CAR T cells. I was totally unaware of all the work going on! When I came to Penn, it just so happened that my path crossed with Jon Epstein,MD [interim dean of the Perelman School of Medicine].
That’s how I learned about the pioneering discoveries in CAR T cell therapy happening here. I came across Carl’s TED Talk, and when I heard the stories about giving those patients back their lives, I found it really inspiring. I thought it would be exciting to be somewhere and do something that could truly change people’s lives. That's why we do science—to help people—and that was one of the reasons why I pursued the field of cell therapy.
There’s no question that over the last decade, CAR T cell therapy has revolutionized cancer. Being given the freedom by Carl, Zolt, and other mentors to explore broadly and ask the question of whether CAR T can work elsewhere—like chronic diseases or aging—and design an ambitious project to find out is something unique to the atmosphere at Penn. I’m hoping to play a role in bringing these next generation therapies to patients and make a real impact over the next decade. I think there’s potential for cell therapy to be a new pillar of medicine at large, and not just a new pillar of oncology!
June: I had a very clear ‘aha moment’ in 2006 when I thought CAR T cell therapy might work. One of the postdocs in my lab (Carmine Carpenito, PhD) burst into my office with the results of an experiment. He looked at the spleen—which is the organ where a lot of T cells live—of a mouse model and found over half of the cells were the CAR T cells we had injected six months earlier. Those cells had formed long-term memory and cured the leukemia. When I saw that, it made me excited at the prospect that these cells might actually work in humans.
Still, I had real doubt as to whether CAR T cells could work in a complex human autoimmune disease like lupus. I was completely astonished when reports started showing up last year that a single infusion of CAR T cells gave people with lupus drug-free remissions, which no other drug has ever done.
Looking ahead, there will be a lot of cell therapy work in autoimmune disease, regenerative medicine, aging diseases, and even dementia and infectious diseases. We’ve already seen several studies for autoimmune diseases get started in a very short period of time. I think in the next couple of decades, we’ll continue to see progress in CAR T cell therapy for more cancer types—and see exponentially more clinical trials coming on board for these other disease areas.
It's important to remember that this progress hasn’t happened by accident. I want to acknowledge the amazing team of scientists, nurses, and physicians here at Penn Medicine that allowed this research to happen. The University of Pennsylvania developed a strategic plan in the 1990s to make Penn a hub for cell and gene therapy, and that early investment is why we now have this large infrastructure and talent in Philadelphia for cell and gene therapy. Supporting science is essential to make future cures possible.